Document:

License Agreement

 Exhibit 10.1 
 EXECUTION VERSION 
 LICENSE AGREEMENT 

This LICENSE AGREEMENT (this “Agreement”), effective as of March 29, 2012 (the “Execution Date”),
is entered into by and between WORLD HEART CORPORATION, a Delaware corporation (“World Heart”) and HEARTWARE INTERNATIONAL, INC., a Delaware corporation (“HeartWare”). World Heart and HeartWare are referred to
herein individually as a “Party” and collectively as the “Parties.” Capitalized terms used in this Agreement that are not defined where first used shall have the meanings given such terms in Section 1
hereof. 
 BACKGROUND 
 WHEREAS, pursuant to that certain Merger Agreement, dated as of March 29, 2012 (the “Merger Agreement”), by and among World Heart, HeartWare and Ocean Acquisition Holding Inc., a
Delaware corporation and wholly owned subsidiary of HeartWare (“Merger Sub”), World Heart, HeartWare and Merger Sub agreed to enter into a business combination transaction pursuant to which Merger Sub will merge with and into World
Heart, with World Heart continuing as the surviving corporation; and 
 WHEREAS, contingent and effective on
the termination of the Merger Agreement by HeartWare or World Heart under the circumstances described in Section 9.03(a) thereof, World Heart has agreed to grant HeartWare a license to the Licensed Patents, on the terms and subject to the
conditions set forth in this Agreement. 
 NOW, THEREFORE, in consideration of the mutual covenants and promises hereinafter set
forth, the Parties agree as follows: 
 AGREEMENT 

 

	1.	DEFINITIONS. As used in this Agreement: 

 1.1 “Affiliate” means, with respect to any Person, any other Person that, directly or indirectly through one (1) or more intermediaries, controls, or is controlled by, or is
under common control with, such Person, and the term “control” (including the terms “controlled by” and “under common control with”) means ownership of fifty percent (50%) or more of the voting
power of the outstanding voting securities (but only as long as such person or entity meets these requirements). 
 1.2
“Change in Control” of HeartWare means (a) any consolidation or merger of HeartWare with or into any other entity in which the holders of such HeartWare’s outstanding shares immediately before such consolidation or
merger do not, immediately after such consolidation or merger, retain stock representing a majority of the voting power of the surviving entity or stock representing a majority of the voting power of an entity that wholly owns, directly or
indirectly, the surviving entity; (b) the sale, transfer, or assignment of securities of HeartWare representing a majority of the voting power of all of HeartWare’s outstanding voting securities to an acquiring party or group; (c) the
sale of all or substantially all of HeartWare’s assets; or (d) any series of related transactions that would fall within clause (a), (b), or (c) above if viewed as a single transaction. 

 1.3 “License Effective Date” means the date on which HeartWare has
made payment in full to World Heart of the License Fee following termination of the Merger Agreement as provided in Section 9.03(a) of the Merger Agreement. 
 1.4 “License Fee” means a one-time, non-refundable fee of Five Hundred Thousand US Dollars ($500,000). 
 1.5 “Licensed Patents” means (i) the patents and patent applications set forth on Exhibit A; and (ii) all foreign counterparts and all reissues, reexaminations,
divisionals, extensions, continuations, continuations in part and continued prosecution applications claiming priority from the patents and patent applications set forth on Exhibit A, but excluding, in each case, any claim of any of the foregoing
that does not claim subject matter disclosed in a patent or patent application listed in Exhibit A hereto. 
 1.6
“Licensed Product” means any product, the manufacture, use, sale, offer for sale or import of which, in the absence of a license under the Licensed Patents, would infringe a claim of a Licensed Patent. 

1.7 “Patent Challenge” means the commencement or assertion by HeartWare or any of its Affiliates, either
directly, or through knowingly providing assistance to a Third Party with respect to any such commencement or assertion, in any lawsuit, other legal proceeding or any administrative proceeding (including, without limitation, any reexamination or
opposition proceeding), of any claim challenging the validity or enforceability of any Licensed Patent or any claim contained in a Licensed Patent, in each case other than (i) in response to a subpoena or pursuant to a command or order by a
governmental authority; (ii) as required by law; or (iii) in connection with a position taken by HeartWare during prosecution of its patents or patent applications. 
 1.8 “Person” means any individual, corporation, partnership, firm, joint venture, association, joint-stock company, trust, unincorporated organization, governmental body or other
entity. 
 1.9 “Term” has the meaning provided in Section 7.1 hereof. 

1.10 “Third Party” means any Person other than the Parties and their respective Affiliates. 

 

	2.	LICENSE 

 2.1 License
Grant. Contingent on the occurrence of, and effective only upon, the License Effective Date, and subject to the terms and conditions of this Agreement, World Heart hereby grants to HeartWare, during the Term, a non-exclusive, worldwide,
royalty-free, nontransferable (except as provided in Section 8.5) license, under the Licensed Patents, solely to 

  
 2 

 
make, have made, use, have used, import, sell, have sold and offer for sale and have offered for sale Licensed Products. The foregoing license shall not include the right to sublicense. However,
HeartWare shall have the right to extend such license to its Affiliates, provided that HeartWare shall be fully responsible for the compliance, and liable for the non-compliance, of its Affiliates with the terms and conditions of this Agreement.

 2.2 Reservation of Rights. All rights not expressly granted by HeartWare in Section 2.1 above are
reserved by World Heart. Without limiting the generality of the foregoing sentence, the Parties acknowledge and agree that nothing in this Agreement shall be construed or interpreted as a grant, by implication or otherwise, of any license under or
right or other covenant with respect to any intellectual property rights other than the license expressly granted by World Heart to HeartWare under Section 2.1 above. 

 

	3.	PAYMENTS 

 3.1
Reimbursement of Patent Costs. HeartWare shall reimburse World Heart for all reasonable and documented costs incurred by World Heart on or after the License Effective Date during the Term for the preparation, filing, prosecution and
maintenance of the Licensed Patents within thirty (30) days of HeartWare’s receipt of invoice therefor (with respect to each Licensed Patent, a “Reimbursable Cost”). At HeartWare’s request, World Heart will
(i) provide information and records concerning invoicing and determination of Reimbursable Costs, and (ii) take into consideration recommendations or requests of HeartWare concerning the preparation, filing, prosecution and maintenance of
the Licensed Patents, including, without limitation, the determination of which jurisdictions in which to make filings. 

3.2 Manner and Place of Payment. All payments owed under this Agreement, including the License Fee, shall be made by wire
transfer to a bank and account designated in writing by World Heart, unless otherwise specified in writing by World Heart. 

3.3 Late Payments. In the event that any payment due under this Agreement is not made when due and not subject to a good
faith dispute by HeartWare, the payment shall accrue interest from the date due at the rate of the one-month LIBOR plus 200 basis points; provided, however, that in no event shall such rate exceed the maximum legal annual interest rate. The
payment of such interest shall not limit World Heart from exercising any other rights it may have as a consequence of the lateness of any payment. 
 3.4 Reduction of Reimbursement Costs. In the event that any Licensed Patent is licensed by World Heart to a Third Party or Third Parties (such Licensed Patent, a “Co-Licensed
Patent”), the Reimbursable Cost payable by HeartWare with respect to such Co-Licensed Patent shall be reduced so as to be equal to the product of (i) the Reimbursable Cost with respect to such Co-Licensed Patent had it not been
licensed to a Third Party or Third Parties; multiplied by (ii) a fraction in which the numerator is one (1) and the denominator is one (1) plus the number of Third Parties that have been granted a license under the Co-Licensed Patent.

  
 3 

 3.5 Terminated Licensed Patents. Effective upon notice from HeartWare to World
Heart of HeartWare’s intention to cease make payments under Section 3.1 with respect to any Licensed Patent(s) specifically identified in such notice (such Licensed Patents, “Terminated Licensed Patents”), the
rights granted to HeartWare under Section 2.1 shall terminate solely with respect to the Terminated Licensed Patents, and HeartWare’s obligation to make payments under Section 3.1 with respect to the Terminated Licensed
Patents shall immediately terminate. 
  

	4.	CONFIDENTIALITY 

 4.1
Confidential Information. Subject to Section 4.3 below, all information disclosed by a Party (as “Disclosing Party”) pursuant to this Agreement that is marked or indicated as confidential or that by its nature
is reasonably understood to be confidential, including, in the case of disclosure by World Heart, information relating to the Licensed Patents or to any of the inventions claimed or disclosed therein, whether orally, in writing, or otherwise, to the
other party (as “Receiving Party”), will be considered “Confidential Information” for purposes of this Agreement. 
 4.2 Protection of Confidential Information. The Receiving Party will not use any Confidential Information of the Disclosing Party for any purpose not allowed by this Agreement, and will
disclose the Confidential Information only to the employees and agents of the Receiving Party who have a need to know such Confidential Information for purposes of this Agreement and who are under a duty of confidentiality no less restrictive than
the Receiving Party’s duty hereunder. The Receiving Party will protect the Confidential Information from unauthorized use, access, or disclosure in the same manner as the Receiving Party protects its own confidential or proprietary information
of a similar nature and with no less than reasonable care. 
 4.3 Exceptions. Confidential Information shall not
include information that the Receiving Party can demonstrate by competent written proof: (a) is now, or hereafter becomes, through no breach of this Agreement by the Receiving Party, generally known or available; (b) is known by the
Receiving Party at the time of receiving such information, as evidenced by its pre-existing written records; (c) is hereafter furnished to the Receiving Party by a Third Party, as a matter of right and without restriction on disclosure; or
(d) is hereafter independently developed by the Receiving Party without use of Confidential Information and without any breach of this Agreement. 
 4.4 Authorized Disclosure. Notwithstanding the provisions of Section 4.2, the Receiving Party may disclose Confidential Information, without violating its obligations under this
Agreement, to the extent the disclosure is required by a valid order of a court or other governmental body of competent jurisdiction or is otherwise required by law or regulation, provided that the Receiving Party shall give reasonable prior
written notice to the Disclosing Party of such required disclosure and, at the Disclosing Party’s request and expense, shall cooperate with the Receiving Party’s efforts to contest such requirement, to obtain a protective order requiring
that the Confidential Information so disclosed be used only for the purposes for which the order was issued or the law or regulation required, and/or to obtain other confidential treatment of such Confidential Information. 

  
 4 

 4.5 Return of Confidential Information. Each Party will return to the other
Party or destroy (and certify the destruction of) all tangible copies of Confidential Information in such Party’s possession or control, except one copy solely for archival purposes, and erase all electronic copies (excluding backup media
generally applied to such Party’s electronic information systems) of Confidential Information promptly upon request following the termination of this Agreement. 
  

	5.	REPRESENTATIONS AND WARRANTIES 

5.1 Mutual Representations and Warranties. Each Party represents and warrants that it has full right, power, and authority
to enter into this Agreement and to perform its obligations and duties under this Agreement. 
 5.2 Warranty
Disclaimer. EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THE INTELLECTUAL
PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES. Without limiting the generality of the foregoing, nothing in this Agreement should be construed as: 

(a) a warranty or representation by World Heart as to the validity, enforceability, or scope of any Licensed Patent;

 (b) a warranty or representation by World Heart that any pending application included in the Licensed Patents
will issue as a patent or that World Heart will prosecute or maintain any of the Licensed Patents; 
 (c) a
warranty or representation by World Heart that it will enforce any Licensed Patent against a Third Party; or 

(d) an obligation by World Heart to furnish any information (including, without limitation, any manufacturing or technical
information) to HeartWare to enable HeartWare to practice the Licensed Patents. 
  

	6.	INDEMNIFICATION 

 Each Party (an
“Indemnifying Party”) will indemnify, defend, and hold harmless the other Party, its Affiliates, and their directors, officers, employees, and agents (collectively, “Indemnitees”) from and against any and all
claims, losses, liabilities, damages, costs, and expenses (including reasonable attorneys’ fees, expert witness fees, and court costs) to which any Indemnitee may become subject as a result of any claim, demand, action or other proceeding by
any Third Party (including product liability actions in the form of tort, warranty or strict liability) to the extent such Losses arise directly or indirectly out of (a) in the case of HeartWare as the Indemnifying Party only, the design,
development, manufacture, use, handling, storage, sale, distribution, or other disposition of any Licensed Product by HeartWare, any of its Affiliates, any 

  
 5 

 
of their manufacturers, suppliers, distributors, agents, representatives, or customers, or (b) in the case of either Party, its breach of this Agreement. HeartWare or World Heart, as
applicable, will use reasonable efforts to notify the Indemnifying Party promptly of any claim for which it believes any Indemnitee is entitled to indemnification under this Section 6. However, the applicable Party’s failure to
provide such notice or delay in providing such notice will relieve the Indemnifying Party of its obligation under this Section 6 to defend the claim only to the extent that such delay or failure prejudices Indemnifying Party’s
ability to defend the claim. If the Indemnifying Party is defending a Third Party claim pursuant to this Section 6, the Indemnitee will have the right to participate in the defense of such claim with their own counsel and at their own
expense. No settlement of any such claim will be binding on an Indemnitee without the Indemnitee’s express prior written consent. 
  

	7.	TERM; TERMINATION 

 7.1
Term. The term of this Agreement (the “Term”) will take effect on the Execution Date, unless earlier terminated in accordance with Section 7.2, shall expire upon expiration of the last-to-expire Licensed
Patent; provided, however, that upon the Effective Time (as such term is defined in the Merger Agreement) or the termination of the Merger Agreement pursuant to Section 9.01 of the Merger Agreement (other than under the circumstances
described in Section 9.03(a) of the Merger Agreement which result in the License Agreement becoming effective), this Agreement shall automatically terminate and be of no further force or effect. 

7.2 Termination. This Agreement may be terminated as follows: 

(a) by mutual written agreement of the Parties; 

(b) by World Heart immediately upon written notice to HeartWare: 

(i) if HeartWare becomes insolvent or is unable to pay its debts as they become due, makes an assignment for the benefit of its
creditors, enters into bankruptcy or similar proceedings, or has a receiver or custodian appointed for it; 
 (ii) if HeartWare
ceases to conduct business or enters into dissolution or liquidation proceedings; or 
 (iii) in the event of a Patent
Challenge. 
 7.3 Effect of Termination. On the effective date of termination of this Agreement pursuant to the
proviso set forth in Section 7.1, or any termination of this Agreement pursuant to Section 7.2 (in either case, the “Termination Date”), all licenses granted by World Heart to HeartWare under this Agreement
will terminate and revert to World Heart, and HeartWare and its Affiliates shall cease to have any right to develop, make, have made, use, sell, have sold, offer for sale, and import Licensed Products. 

  
 6 

 7.4 Survival. Neither expiration nor any termination of this Agreement shall
relieve either Party of any obligation or liability accruing prior to such expiration or termination, nor shall expiration or any termination of this Agreement preclude either Party from pursuing all rights and remedies it may have under this
Agreement, at law or in equity, with respect to breach of this Agreement. In addition, Section 1 (Definitions), Section 3.2 (Manner and Place of Payment), Section 3.3 (Late Payments), Section 4
(Confidentiality), Section 5.2 (Warranty Disclaimer), Section 6 (Indemnification), Section 7.3 (Effect of Termination), Section 7.4 (Survival), and Section 8 (General) shall survive
expiration or termination of this Agreement. 
  

	8.	GENERAL 

 8.1
Governing Law. This Agreement and any other document or instrument delivered pursuant hereto, and all claims or causes of action (whether in contract or tort) that may be based upon, arise out of, or relate to this Agreement, shall be
governed by and construed in accordance with the laws of the State of New York, excluding its conflicts of law rules. 
 8.2
Payment of Fees and Expenses by Breaching Party. In addition to any amounts awarded to a Party hereunder upon a final, non-appealable judgment by a court of competent jurisdiction that the other Party has breached the terms or conditions
of this Agreement, the non-breaching Party shall be entitled to reimbursement by the breaching Party for reasonable attorney’s fees and other expenses incurred by it in connection with the claim, demand, action or other
proceeding in respect of such breach. 
 8.3 Export Law. HeartWare will comply with all applicable export and
import control laws and regulations in its manufacturing, use, and distribution of the Licensed Products. In particular, HeartWare will not export or re-export the Licensed Products or any technical data or confidential information derived from or
pertaining to the Licensed Products or Licensed Patents without all required U.S. and foreign government licenses. 
 8.4
Injunctive Relief. The Parties hereby acknowledge and agree that in the event of any breach of this Agreement by a Party, the other Party may suffer an irreparable injury such that no remedy at law would adequately protect or
appropriately compensate such other Party for such injury. Accordingly, the Parties shall have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without prejudice to any
other rights and remedies that a Party may have for a breach of this Agreement. 
 8.5 Assignment. HeartWare may
not assign or transfer any of its rights or delegate any of its obligations or duties under this Agreement (by operation of law or otherwise) without World Heart’s prior written consent; provided, however, that HeartWare may, without the
consent of World Heart, assign or transfer any of its rights or delegate any of its obligations or duties under this Agreement to an Affiliate or to a successor of HeartWare upon a Change in Control. Any attempted assignment or transfer (by
operation of law or otherwise) or attempted delegation without such consent will be null and void. This Agreement will be binding upon and inure to the benefit of the Parties and their respective permitted successors and permitted assigns.

  
 7 

 8.6 Bankruptcy. All rights and licenses granted under or pursuant to this
Agreement by either Party are, and will otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code, licenses of right to “intellectual property” as defined under Section 101 of the United
States Bankruptcy Code. 
 8.7 Waiver. The waiver from time to time by either Party of any right or the failure of
either Party to exercise any remedy shall not operate or be construed as a continuing waiver of the same right or remedy or of any other of such Party’s rights or remedies provided under this Agreement. All waivers provided under this Agreement
must be in writing and signed by both Parties. 
 8.8 Independent Contractors. It is expressly agreed that the
Parties are independent contractors and that the relationship between the Parties shall not constitute a partnership, joint venture or agency of any kind. Neither Party shall have the authority to make any statements, representations or commitments
of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party. 
 8.9 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same
instrument. 
 8.10 Severability. If any provision of this Agreement is declared by a court of competent
jurisdiction to be invalid, void or unenforceable, then such provision will be changed and interpreted to accomplish the objectives of such provision to the greatest extent possible under applicable law, and the remaining provisions of this
Agreement will continue in full force and effect. 
 8.11 Notice. All notices and other communications under this
Agreement shall be in writing and shall be deemed given (a) when delivered personally by hand (with written confirmation of receipt), (b) when sent by facsimile (with written confirmation of transmission), (c) one (1) Business
Day following the day sent by overnight courier (with written confirmation of receipt) or (d) when sent by email (with confirmation of receipt of such email), in the case of clauses (a), (b), (c) and (d), to the address, facsimile number
or email address set forth beneath the name of such Party below (or to such other address, facsimile number or email address as such Party may have specified in a written notice to the other Party). 

if to HeartWare: 

HeartWare International, Inc. 
 205 Newbury Street, Suite 101 
 Framingham, MA 01701 

					
		 	 Attention:
	 	Lawrence Knopf
		 	 Telephone:
	 	(508) 739-0950
		 	 Facsimile:
	 	(508) 739-0948
		 	 Email:
	 	lknopf@heartwareinc.com

  
 8 

 with a copy (which shall not constitute notice) to: 

Shearman & Sterling LLP 
 599 Lexington Avenue 
 New York, NY 10022 

					
		 	 Attention:
	 	Clare O’Brien
		 		 	Robert Katz
		 	 Telephone:
	 	(212) 848-4000
		 	 Facsimile:
	 	(212) 848-7179
		 	 Email:
	 	cobrien@shearman.com
		 		 	robert.katz@shearman.com

 if to World Heart: 

World Heart Corporation 
 4750 Wiley Post Way 
 Suite 120 

Salt Lake City, Utah 84116 

					
		 	 Attention:
	 	Morgan Brown
		 	 Telephone:
	 	(801) 303-4361
		 	 Facsimile:
	 	(801) 355-7622
		 	 Email:
	 	morgan.brown@worldheart.com

 with a copy (which shall not constitute notice) to: 

Cooley LLP 
 3175
Hanover Street 
 Palo Alto, CA 94304-1130 

					
		 	 Attention:
	 	Mark Weeks
		 	 Facsimile:
	 	(650) 618-2034
		 	 Email:
	 	mweeks@cooley.com

 and with a copy (which shall not constitute notice) to: 

Cooley LLP 
 4401
Eastgate Mall 
 San Diego, CA 92121 

					
		 	 Attention:
	 	Barbara L. Borden
		 	 Facsimile:
	 	(858) 550-6420
		 	 Email:
	 	bordenbl@cooley.com

 8.12 Construction. The section headings in this Agreement are for convenience of reference
only, will not be deemed to be a part of this Agreement, and will not be referred to in connection with the construction or interpretation of this Agreement. Any rule of construction to 

  
 9 

 
the effect that ambiguities are to be resolved against the drafting Party will not be applied in the construction or interpretation of this Agreement. As used in this Agreement, the words
“include” and “including,” and variations thereof, will not be deemed to be terms of limitation, but rather will be deemed to be followed by the words “without limitation.” 

8.13 Entire Agreement. This Agreement (including all Exhibits hereto) and, to the extent referenced in this Agreement, the
Merger Agreement set forth the entire agreement and understanding between the Parties with respect to the subject matter hereof, and supersede and terminate all prior agreements and understandings between the Parties with respect to the subject
matter hereof. No subsequent amendment, modification or addition to this Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers of the Parties. 

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 10 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Execution Date.

  

			
	HEARTWARE INTERNATIONAL, INC
		
	By:	 	 /s/ Doug Godshall

	Name:	 	 Doug Godshall

	Title:	 	 President/CEO

	
	 WORLD HEART CORPORATION

		
	By:	 	 /s/ John Alexander Martin

	Name:	 	 John Alexander Martin

	Title:	 	 President & CEO

 [Signature Page – License Agreement]Second Amendment to Credit Agreement

 Exhibit 10.1 
 SECOND AMENDMENT TO CREDIT AGREEMENT 
 This Second Amendment to Credit
Agreement (this “Amendment”) is entered into as of April 2, 2012, among Compass Group Diversified Holdings LLC, a Delaware limited liability company (“Borrower”), Toronto Dominion (Texas) LLC, as Agent for the
Lenders, and the undersigned Lenders. 
 W I T N E S S E T H 

WHEREAS, Borrower, Lenders and Agent are parties to that certain Credit Agreement dated as of October 27, 2011 (as amended to date,
the “Credit Agreement”; capitalized terms used herein and not otherwise defined herein shall have the respective meanings given to them in the Credit Agreement); 

WHEREAS, Borrower has requested that the Lenders holding portions of the Term Loan agree to amend the Credit Agreement in certain
respects; 
 NOW, THEREFORE, in consideration of the mutual agreements, provisions and covenants contained herein, the parties
hereto agree as follows: 
 1. Amendments to Credit Agreement. Subject to the terms and conditions contained herein, the
parties hereto hereby agree to amend the Credit Agreement as follows: 
 (a) The first paragraph of the definition of
“Applicable Margin” in Section 1.1 of the Credit Agreement is hereby amended and restated in its entirety as follows: 
 “With respect to the Term Loan, the Applicable Margin shall mean (i) 4.00%, in the case of the portion of the Term Loan comprised of Base Rate Loans and (ii) 5.00%, in the case of the
portion of the Term Loan comprised of LIBOR Loans.” 
 (b) The proviso to the definition of “LIBOR Rate” in
Section 1.1 of the Credit Agreement is hereby amended by replacing each reference therein to “1.50%” with a reference to “1.25%”. 
 (c) Section 2.10.1 of the Credit Agreement is hereby amended by replacing the reference therein to “October 27, 2012” with a reference to “the first anniversary of the date of
effectiveness of that certain Second Amendment to this Agreement, dated as of April 2, 2012, among Borrower, the Agent and certain Lenders,” 
 2. Representations and Warranties of Borrower. Borrower hereby represents and warrants to Agent and Lenders that, both before and after giving effect to this Amendment: 

(a) The execution, delivery and performance of this Amendment has been duly authorized by all requisite corporate action on the part of
Borrower; 
 (b) No Default or Event of Default has occurred and is continuing; and 

(c) The representations and warranties of Borrower set forth in the Credit Agreement, as amended hereby, and in the other Loan Documents,
as amended hereby, are true and correct in all material respects as of the date hereof, with the same effect as though made on the date hereof (except to the extent such representations and warranties expressly refer to an earlier date, in which
case they are true and correct in all material respects as of such earlier date). 

 3. Conditions Precedent to Effectiveness. This Amendment shall become effective on
the date when each of the following conditions shall have been fulfilled to the satisfaction of the Agent: 
 (a) Agent shall
have received a copy of this Amendment executed by Borrower, Agent and each Lender holding a portion of the Term Loan, together with such other documents, agreements and instruments as Agent may reasonably require or request in connection herewith;

 (b) Borrower shall have paid to each Lender a fully earned, non-refundable fee in an amount equal to 1.00% of the outstanding
portion of the Term Loan owed to such Lender; and 
 (c) no Default or Event of Default shall have occurred and be continuing or
shall be caused by the transactions contemplated by this Amendment. 
 4. Miscellaneous. 

(a) Governing Law. THIS AMENDMENT SHALL BE A CONTRACT MADE UNDER AND GOVERNED BY THE INTERNAL LAWS OF THE STATE OF NEW YORK.

 (b) Counterparts. This Amendment may be executed in any number of counterparts, and by the parties hereto on the same
or separate counterparts, and each such counterpart, when executed and delivered, shall be deemed to be an original, but all such counterparts shall together constitute but one and the same Amendment. 

(c) Reference to Credit Agreement. Each reference in the Credit Agreement to “this Agreement,” “hereunder,”
“hereof,” “herein” or words of like import, and each reference in the Credit Agreement or in any other Loan Document, or other agreements, documents or other instruments executed and delivered pursuant to the Credit Agreement,
shall mean and be a reference to the Credit Agreement as amended by this Amendment. 
 (d) Costs and Expenses. Borrower
acknowledges that Section 10.4 of the Credit Agreement applies to this Amendment and the transactions, agreements and documents contemplated hereunder. 
 [Signature Page Follows] 

  
 2 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed and
delivered by their duly authorized officers as of the day and year first above written. 
  

			
	COMPASS GROUP DIVERSIFIED HOLDINGS LLC
		
	By:	 	 /s/ James J. Bottiglieri

	Title:	 	 Chief Financial Officer

 
			
	 TORONTO DOMINION (TEXAS) LLC,
 as Agent

		
	By:	 	 /s/ Bebi Yasin

	Title:	 	 Authorized Signatory

  

			
	TD BANK, N.A.,
	as a Lender
		
	By:	 	 /s/ Todd Antico

	Title:	 	 Senior Vice President

			
	 TORONTO DOMINION (TEXAS) LLC,
 as a Lender

		
	By:	 	 /s/ Bebi Yasin

	Title:	 	 Authorized Signatory

 AMMC VII, LIMITED 
 AMMC CLO IX, LIMITED 
 AMMC CLO X, LIMITED 

 

							
		 		 	By:	 	American Money Management Corp.,
		 		 		 	as Collateral Manager
		 	as a Lender

  

			
	By:	 	 /s/ David P. Meyer

	Name:	 	 David P. Meyer

	 Title:
	 	 Senior Vice President

  

			
	ASF1 LOAN FUNDING LLC,
	as a Lender
	
	 /s/ Lynette Thompson

	By:	 	 Lynette Thompson

	Title:	 	 Director

  

			
	 AUDAX CREDIT OPPORTUNITIES OFFSHORE LTD.,

	 as a Lender

	
	 /s/ Michael P. McGonigle

	 By:
	 	 Michael P. McGonigle

	 Title:
	 	 Authorized Signatory

  

			
	AUDAX CREDIT OPPORTUNITIES (SBA), LLC,
	as a Lender
		 	
	 /s/ Michael P. McGonigle

	By:	 	 Michael P. McGonigle

	Title:	 	 Authorized Signatory

			
	BMO HARRIS FINANCING, INC.,
	as a Lender
	
	 /s/ Katherine K. Robinson

	By:	 	 Katherine K. Robinson

	Title:	 	 Vice President

  

			
	BRANCH BANKING AND TRUST COMPANY,
	as a Lender
		
	By:	 	 /s/ Steve W. Whitcomb

	Title:	 	 Senior Vice President

  

			
	
	 /s/ Joe Morin

	as a Lender
		
	By:	 	 Joe Morin

	Title:	 	
Vice President – Canso Investment Counsel Ltd.

		
	For:	 	 Conso Bank Loan Fund

 BRIDGEPORT CLO LTD. 
 SCHILLER PARK CLO LTD. 
 BURR RIDGE CLO PLUS LTD. 

BRIDGEPORT CLO II LTD. 
  

			
	By:	  	Deerfield Capital Management LLC, their
	Collateral Manager

  

			
	By:	 	 /s/ Stephen J. Vaccaro

	Name:	 	 Stephen J. Vaccaro

	Title:	 	 Authorized Signatory

 HEWETT’S ISLAND CLO V, LTD. 
 HEWETT’S ISLAND CLO VI, LTD. 
 PRIMUS CLO I, LTD. 

PRIMUS CLO II, LTD. 
  

			
	By:	  	CypressTree Investment Management, LLC, their
	Collateral Manager

  

			
	By:	 	 /s/ Stephen J. Vaccaro

	Name:	 	 Stephen J. Vaccaro

	Title:	 	 Authorized Signatory

 COLUMBUSNOVA CLO LTD. 2006-I 
 COLUMBUSNOVA CLO LTD. 2006-II 
 COLUMBUSNOVA CLO LTD. 2007-I 

COLUMBUSNOVA CLO IV LTD. 2007 
  

			
	 By:
	  	Columbus Nova Credit Investments
	 Management, LLC, its Collateral Manager

  

			
	By:	 	 /s/ Stephen J. Vaccaro

	Name:	 	 Stephen J. Vaccaro

	Title:	 	 Authorized Signatory

 CIFC FUNDING 2006-I, LTD. 
 CIFC FUNDING 2006-IB, LTD. 
 CIFC FUNDING 2006-II, LTD. 

CIFC FUNDING 2007-I, LTD. 
 CIFC FUNDING 2007-II,
LTD. 
 CIFC FUNDING 2007-III, LTD. 

CIFC FUNDING 2007-IV, LTD. 
 CIFC FUNDING 2011-I,
LTD. 
  

			
	 By:
	  	CIFC Investment Management LLC,
	 its Collateral Manager

  

			
	By:	 	 /s/ Stephen J. Vaccaro

	Name:	 	 Stephen J. Vaccaro

	Title:	 	 Authorized Signatory

  

			
	FIFTH THIRD BANK, an Ohio banking corporation,
	as a Lender
	
	 /s/ Philip Renwick

	By:	 	 Philip Renwick

	Title:	 	 Vice President

 GOLDENTREE LOAN OPPORTUNITIES III, LIMITED 

 

			
	 By:
	 	GoldenTree Asset Management, LP,
	 as a Lender

		
	 By:
	 	 /s/ Karen Weber

	 Title:
	 	 Director – Bank Debt

 GOLDENTREE LOAN OPPORTUNITIES IV, LIMITED 

 

			
	By:	 	GoldenTree Asset Management, LP,
	as a Lender
		
	By:	 	 /s/ Karen Weber

	Title:	 	 Director – Bank Debt

 GOLDENTREE LOAN OPPORTUNITIES V, LIMITED 

 

			
	By:	 	GoldenTree Asset Management, LP,
	as a Lender
		
	By:	 	 /s/ Karen Weber

	Title:	 	 Director – Bank Debt

 THE UNIVERSITY OF CHICAGO 
  

			
	By: GoldenTree Asset Management, LP,
	as a Lender
		
	By:	 	 /s/ Karen Weber

	Title:	 	 Director – Bank Debt

 SC PRO LOAN II LIMITED 
  

			
	By:	 	GoldenTree Asset Management, LP,
	as a Lender
		
	By:	 	 /s/ Karen Weber

	Title:	 	 Director – Bank Debt

 SWISS CAPITAL PRO LOAN III PLC 
  

			
	By:	 	GoldenTree Asset Management, LP,
	as a Lender
		
	By:	 	 /s/ Karen Weber

	Title:	 	 Director – Bank Debt

 GOLUB INTERNATIONAL LOAN LTD. I, 
 as a Lender 
  

			
	By:	 	Golub Capital International Management LLC,
	as a Collateral Manager
	
	 /s/ Christina D. Jamieson

		
	By:	 	 Christina D. Jamieson

	Title:	 	 Authorized Signatory

  

 GOLUB CAPITAL MANAGEMENT CLO 2007-1, LTD, 
 as a Lender 
  

			
	By:	 	Golub Capital LLC,
	as a Collateral Manager

  

			
	 /s/ Christina D. Jamieson

	By:	 	 Christina D. Jamieson

	Title:	 	 Authorized Signatory

 GOLUB CAPITAL PARTNERS FUNDING 2007-1 LTD., 
 as a Lender 
  

			
	By:	 	Golub Capital Incorporated,
	as Servicer
	
	 /s/ Christina D. Jamieson

	By:	 	 Christina D. Jamieson

	Title:	 	 Authorized Signatory

 GOLUB CAPITAL SENIOR LOAN OPPORTUNITY FUND, LTD., 
 as a Lender 
  

			
	By:	 	GC Advisors LLC, as agent
	
	 /s/ Christina D. Jamieson

	By:	 	 Christina D. Jamieson

	Title:	 	 Authorized Signatory

 GOLUB CAPITAL FUNDING CLO-8, LTD, 
 as a Lender 
  

			
	By:	 	Golub Capital Partners Management Ltd,
	as Collateral Manager
	
	 /s/ Christina D. Jamieson

	By:	 	 Christina D. Jamieson

	Title:	 	 Authorized Signatory

 GC ADVISORS LLC as Agent for United Insurance Company of America, 

as a Lender 
  

			
	 /s/ Christina D. Jamieson

		
	By:	 	 Christina D. Jamieson

	Title:	 	 Authorized Signatory

 GOLUB CAPITAL BDC FUNDING LLC, 
 as a Lender 
  

			
	By:	 	GC Advisors LLC, as agent
	
	 /s/ Christina D. Jamieson

		
	By:	 	 Christina D. Jamieson

	Title:	 	 Authorized Signatory

 GC ADVISORS LLC as Agent for Federal Insurance Company, 
 as a Lender 
  

			
	 /s/ Christina D. Jamieson

		
	By:	 	 Christina D. Jamieson

	Title:	 	 Authorized Signatory

 GOLUB CAPITAL PEARLS DIRECT LENDING PROGRAM, L.P., 
 as a Lender 
  

			
	By:	 	GC Advisors LLC, its Manager
	
	 /s/ Christina D. Jamieson

	By:	 	 Christina D. Jamieson

	Title:	 	 Authorized Signatory

 GOLUB CAPITAL PARTNERS CLO 10, LTD., 
 as a Lender 
  

			
	By:	 	GC Advisors LLC, its Agent
	
	 /s/ Christina D. Jamieson

		
	By:	 	 Christina D. Jamieson

	Title:	 	 Authorized Signatory

 GC ADVISORS LLC as Agent for Ironshore Specialty 
 Insurance Company, 
 as a Lender 

 

			
	 /s/ Christina D. Jamieson

		
	By:	 	 Christina D. Jamieson

	Title:	 	 Authorized Signatory

 GC ADVISORS LLC as Agent for Lincoln Investment 
 Solutions, Inc., 
 as a Lender 

 

			
	 /s/ Christina D. Jamieson

		
	By:	 	 Christina D. Jamieson

	Title:	 	 Authorized Signatory

  

			
	MADISON CAPITAL FUNDING LLC,
	as a Lender
		
	By:	 	 /s/ Kevin Bolash

	Title:	 	 Kevin Bolash, Senior Vice President

 VENTURE V CDO LIMITED, 
 as a Lender 
  

			
	By:	 	its investment advisor, MJX Asset Management, LLC
		
	By:	 	 /s/ Michael Regan

	Title:	 	 Managing Director

 VENTURE VI CDO LIMITED, 
 as a Lender 
  

			
	By:	 	its investment advisor, MJX Asset Management, LLC
		
	By:	 	 /s/ Michael Regan

	Title:	 	 Managing Director

 VENTURE VII CDO LIMITED, 
 as a Lender 
  

			
	By:	 	its investment advisor, MJX Asset Management, LLC
		
	By:	 	 /s/ Michael Regan

	Title:	 	 Managing Director

 VENTURE VIII CDO, LIMITED, 
 as a Lender 
  

			
	By:	 	its investment advisor, MJX Asset Management, LLC
		
	By:	 	 /s/ Michael Regan

	Title:	 	 Managing Director

 VENTURE IX CDO, LIMITED, 
 as a Lender 
  

			
	By:	 	its investment advisor, MJX Asset Management, LLC
		
	By:	 	 /s/ Michael Regan

	Title:	 	 Managing Director

  

			
	MORGAN STANLEY BANK, N.A.,
	as a Lender
	
	 /s/ Harry Comninellis

	By:	 	 Harry Comninellis

	Title:	 	 Authorized Signatory

 NEWSTAR CP FUNDING LLC 
  

			
	By:	 	NewStar Financial, Inc., its Designated Manager
		
	By:	 	 /s/ Michael J. Faherty Jr.

	Name:	 	 Michael J. Faherty Jr.

	Title:	 	 Director

 NEWSTAR CREDIT OPPORTUNITIES FUNDING II LTD. 

 

			
	By:	 	NewStar Financial, Inc., its Manager
		
	By:	 	 /s/ Michael J. Faherty Jr.

	Name:	 	 Michael J. Faherty Jr.

	Title:	 	 Director

 NEWSTAR COMMERCIAL LOAN FUNDING 2012-1 LLC 

 

			
	By:	 	NewStar Financial, Inc., its Designated Manager
		
	By:	 	 /s/ Michael J. Faherty Jr.

	Name:	 	 Michael J. Faherty Jr.

	Title:	 	 Director

 NEWSTAR SHORT-TERM FUNDING LLC 

 

			
	By:	 	NewStar Financial, Inc., its Designated Manager
		
	By:	 	 /s/ Michael J. Faherty Jr.

	Name:	 	 Michael J. Faherty Jr.

	Title:	 	 Director

 DAVIDSON RIVER TRADING, LLC, 
 as a Lender 
  

			
	By:	 	SunTrust Bank, its Manager
		
	By:	 	 /s/ Douglas Weltz

	Title:	 	 Director

  

			
	SUNTRUST BANK,
	as a Lender
		
	By:	 	 /s/ Christopher Fellows

	Title:	 	 Portfolio Manager, Middle Market Banking

 TELOS CLO 2006-1, LTD 
 TELOS CLO 2007-2, LTD 
  

			
	By:	 	Tricadia Loan Management, LLC
		
	By:	 	 /s/ Jonathan Tepper

	Title:	 	 Jonathan Tepper, Director

  

			
	U.S. BANK NATIONAL ASSOCIATION,
	as a Lender
		
	By:	 	 /s/ Jason Nadler

	Title:	 	 Vice President

 WEBSTER BANK, 

as a Lender 
  

			
	By:	 	 /s/ Robert W. Towns

	Title:	 	 Senior Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00202-of-00352.parquet"}]]